General
Preferred name
ETORICOXIB
Synonyms
Etoricoxib D4 ()
MK-0663 D4 ()
L-791456 D4 ()
Arcoxia ()
MK-663 ()
Tauxib ()
L-791456 ()
Nucoxia ()
DESVENLAFAXINE ()
MK-0663 ()
Arcoxia, MK-663, MK-0663, Tauxib, Algix, Nucoxia ()
P&D ID
PD009436
CAS
202409-33-4
Tags
available
drug
First approval
2002
1998
Drug indication
rheumatic disease
Rheumatoid arthritis
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Etoricoxib is a COX-2 selective inhibitor (approximately 106 times more selective for COX-2 inhibition over COX-1).
MOA Like any other COX-2 selective inhibitor Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2), preventing production of prostaglandins (PGs) from arachidonic acid.
DESCRIPTION Etoricoxib is a selective COX-2 inhibitor, non-steroidal anti-inflammatory (NSAID) drug.

COVID-19: Etoricoxib offers potential to be repositioned to inhibit cytokine storm in COVID-19 patients . (GtoPdb)
PRICE 29
DESCRIPTION Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC50s of 1.1 ¦ÌM and 116 ¦ÌM for COX-2 and COX-1 in human whole blood.
DESCRIPTION Etoricoxib is a COX-2 selective inhibito. Etoricoxib is a non steroidal anti-inflammatory agent, has antipyretic, analgesic, and potential antineoplastic properties. (Enamine Bioactive Compounds)
DESCRIPTION Etoricoxib (MK-663) is a synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and potential antineoplastic properties. Etoricoxib specifically binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in inhibition of the conversion of arachidonic acid into prostaglandins. Inhibition of COX-2 may induce apoptosis and inhibit tumor cell proliferation and angiogenesis. (TargetMol Bioactive Compound Library)
Compound Sets
25
Cayman Chemical Bioactives
10091
ChEMBL Approved Drugs
CHEMBL416146
ChEMBL Drugs
CHEMBL416146
Concise Guide to Pharmacology 2017/18
2896
Concise Guide to Pharmacology 2019/20
2896
Drug Repurposing Hub
DrugBank
DB01628
DrugBank Approved Drugs
DB01628
DrugCentral
1113
DrugCentral Approved Drugs
1113
DrugMAP
DM6A4NW
DrugMAP Approved Drugs
DM6A4NW
Enamine Bioactive Compounds
EBC-00675
Guide to Pharmacology
2896
Ki Database
ETORICOXIB
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL416146
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
CHEMBL416146
MedChem Express Bioactive Compound Library
HY-15321
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
etoricoxib
TargetMol Bioactive Compound Library
T1574
External IDs
43
Properties
(calculated by RDKit )
Molecular Weight
358.05
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
0
Rotatable Bonds
3
Ring Count
3
Aromatic Ring Count
3
cLogP
4.18
TPSA
59.92
Fraction CSP3
0.11
Chiral centers
0.0
Largest ring
6.0
QED
0.7
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
COX
PTGS2
Pathway
Immunology/Inflammation
Neuroscience
Member status
member
MOA
Cyclooxygenase-2 Inhibitors
Non-Steroidal Antiinflammatory Drugs
cyclooxygenase inhibitor
Indication
rheumatoid arthritis, psoriatic arthritis, osteoarthritis, gout, ankylosing spondylitis
Therapeutic Class
Antiinflammatory Agents
Source data